Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.
Amin HaideraliWhitney C RhodesSantosh GautamMin HuangJan SielukKaren E SkinnerLee S SchwartzbergPublished in: Future oncology (London, England) (2021)
Background: This retrospective, observational study examined real-world treatment patterns and effectiveness outcomes in 450 patients with stage II-IIIB early-stage triple-negative breast cancer treated in the community oncology setting. Methods: Kaplan-Meier methods were used to evaluate event-free survival (EFS), time to recurrence and overall survival (OS). Cox regression models were used to evaluate predictors of EFS and OS by pathological complete response (pCR) status. Results: Among patients receiving neoadjuvant systemic therapy only, pCR was a predictor of EFS and OS. Conclusion: These results highlight the unmet need for therapies that improve outcomes for patients with early-stage triple-negative breast cancer including increasing rates of pCR among patients receiving neoadjuvant therapy.
Keyphrases
- early stage
- free survival
- randomized controlled trial
- rectal cancer
- systematic review
- sentinel lymph node
- lymph node
- locally advanced
- mental health
- palliative care
- squamous cell carcinoma
- stem cells
- type diabetes
- metabolic syndrome
- adipose tissue
- skeletal muscle
- mesenchymal stem cells
- real time pcr
- glycemic control
- cell therapy
- neoadjuvant chemotherapy